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ABSTRACT
Introduction: Plaque psoriasis is a chronic skin
disease where genital involvement is relatively
common. Yet health care providers do not
routinely evaluate psoriasis patients for genital
involvement and patients do not readily initiate
discussion of it.
Methods: A qualitative study of 20 US patients
with dermatologist-confirmed genital psoriasis
(GenPs) and self-reported moderate-to-severe
GenPs at screening was conducted to identify
key GenPs symptoms and their impacts on
health-related quality of life (HRQoL).
Results: Patients had a mean age of 45 years,
55% were female, and patients had high rates of
current/recent moderate-to-severe overall (65%)
and genital (70%) psoriasis. Patients reported
the following GenPs symptoms: genital itch
(100%), discomfort (100%), redness (95%),
stinging/burning (95%), pain (85%), and scaling
(75%). Genital itching (40%) and stinging/
burning (40%) were the most bothersome
symptoms. Impacts on sexual health included
impaired sexual experience during sexual
activity (80%), worsening of symptoms after
sexual activity (80%), decreased frequency of
sexual activity (80%), avoidance of sexual
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relationships (75%), and reduced sexual desire
(55%). Negative effects on sexual experience
encompassed physical effects such as mechani-
cal friction, cracking, and pain as well as psy-
chosocial effects such as embarrassment and
feeling stigmatized. Males reported a higher
burden of symptoms and sexual impacts. Other
HRQoL impacts were on mood/emotion (95%),
physical activities (70%), daily activities (60%),
and relationships with friends and family
(45%). These impacts significantly affected daily
activities. Physical activities were affected by
symptoms and flares, and increased sweat and
friction worsened symptoms. Patients reported
daily practices to control outcomes.
Conclusion: The high level of reported symp-
toms and sexual and nonsexual impacts reflects
the potential burden of moderate-to-severe
GenPs. GenPs can impact many facets of
HRQoL and providers should evaluate their
patients for the presence of genital psoriasis and
its impact on their quality of life.
Funding: Eli Lilly and Company.
PLAIN LANGUAGE SUMMARY
Background: Psoriasis is a skin disease that can
cause itchy, raised red patches of skin. Cur-
rently, psoriasis cannot be cured but medicines
can make the patches smaller or go away com-
pletely. The patches can occur anywhere on the
body. Sometimes people get them in their gen-
ital area. However, people are sensitive about
this area and may not tell their doctor. Their
doctor may not look or ask either.
What We Did: We interviewed 20 men and
women who had moderate-to-severe genital
psoriasis. We asked about their health-related
quality of life, including their sex life.
What We Learned: All 20 people said they had
symptoms of itching and discomfort in their
genital area. Most people also had symptoms of
redness, stinging or burning, pain, and scaling
(flaky skin). Most people said symptoms affected
their sex life. Sexual activity was less comfort-
able. People had sexual activity less often.
Physical reasons, such as pain, bothered some
people. Emotional reasons, such as being
embarrassed, bothered other people more. Peo-
ple said the genital psoriasis affected how they
felt. For example, it made them stressed, angry,
or sad. Genital psoriasis made physical activities
such as walking and running more uncomfort-
able for many people, especially when symp-
toms ‘‘acted up.’’ Sweating a lot, wearing tight
underwear, or working a long day could make
symptoms worse too. About half the people
spent less time with their family and friends
because of their symptoms. People also did
things to try to reduce their symptoms. Some
people wore loose clothes or soaked in a bathtub
every night or after sex. Other people carried
cream (to stop the itch) with them all the time.
Conclusion: Other people may not experience
what these 20 people did. However, having
genital psoriasis can significantly impact some-
one’s life. Patients and doctors should talk
about it.
Keywords: Burden of illness; Genital psoriasis;
Health-related quality of life; Qualitative
research
INTRODUCTION
Plaque psoriasis is a chronic inflammatory skin
disease which can affect multiple body areas
with different degrees of severity. Involvement
of the genital area at some point in the disease
course is relatively common. Many patients
with psoriasis (32%–63%) reported current or
past genital involvement in survey-based
research [1–5], and 38% had current genital
involvement confirmed by physical exam [5, 6].
The unique microenvironment of moisture,
warmth, and friction can lead to fissures, ero-
sion, and maceration, and can also reduce the
appearance of scaling [7–10]. Red thin plaques
and lack of scale are characteristic of genital
psoriasis (GenPs) and can lead to misidentifica-
tion by the patient (e.g., a sexually transmitted
disease) and by health care providers (e.g., der-
matitis or tinea) [9, 11, 12].
Compared to psoriasis patients without
genital involvement, psoriasis patients with
genital involvement report statistically signifi-
cantly worse health-related quality of life
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(HRQoL) [3, 5] and statistically significantly
greater impact on sexual health and relation-
ships [5, 13]. Women with genital psoriasis
reported statistically significantly higher sexual
distress than women without it [3]. Psoriasis
patients with involvement of ‘‘sensitive’’ regions
(the lower abdomen and genitals) report greater
feelings of stigmatization compared to patients
with visible hand, scalp, neck, and facial lesions
[14]. However, despite this impact of genital
symptoms, patients frequently do not broach
the subject with their health care providers
[4, 13]. Similarly, providers neither commonly
question nor examine patients for its presence
[3, 15]. More detailed descriptions from patients
on the impact of GenPs may help encourage
providers to identify and ultimately appropri-
ately treat patients with GenPs. A qualitative
study was undertaken of patients with GenPs to
identify key GenPs symptoms and their impact
on HRQoL from the patients’ perspectives.
METHODS
Study Design
This was a cross-sectional, qualitative study of 20
male and female patients with GenPs. A targeted
literature review and input from two US-based
clinicians specializing in dermatology and
research into general psoriasis andGenPs (authors
CR and SF) led to the development of the draft
conceptual model which underlies the
semi-structured interview guide. The model
(Fig. S1 in the Electronic supplementary material,
ESM) asserts that (1) GenPs symptoms influence
short-term functional outcomes and (2) these
short-term functional outcomes have distal
impacts, including sexual and social endpoints.
The interview comprised two components:
concept elicitation and cognitive interviews.
During concept elicitation, patients were asked
an open-ended question about the GenPs
symptoms they experienced (without any defi-
nition of symptoms) and were then probed for
more detail on the symptoms they reported as
well as on predefined symptoms of itching,
pain, scaling, discomfort, redness, and stinging/
burning, whether spontaneously reported or
not. The same pattern was followed for sexual
health and HRQoL: open-ended questions fol-
lowed by specific topic probes. Predefined sex-
ual health topics were sexual desire, sexual
experience, sexual frequency, worsening of
symptoms after sexual activity, and avoidance
of sexual relationships. Predefined HRQoL
topics were physical activities, mood or emo-
tional status, social or leisure activities, work/
school, daily activities, and relationships with
family/friends. Responses were both sponta-
neous and probed. During the cognitive inter-
views, patients completed two draft
patient-report outcomes (PRO) measures, the
Sexual Function Questionnaire and Genital
Psoriasis Symptom Severity, and were asked for
their feedback on the measures. Data from these
two PROs will be covered in separate manu-
scripts. The study was conducted in accordance
with the Declaration of Helsinki, good clinical
practice, and all applicable laws and regula-
tions. Although informed consent and institu-
tional review board (IRB) oversight were waived
by the local IRB (Chesapeake IRB, Columbia,
MD), all participants gave written and verbal
informed consent prior to commencing the
interview.
Patient Recruitment
Patients were recruited in the continental USA
by clinical staff from five clinical sites located in
four states (Arkansas, Indiana, Michigan, and
Washington). Clinical staff identified potential
participants through review of clinical charts
and screened them for study eligibility either in
person or over the telephone. All patients had
current or past GenPs confirmed by a derma-
tologist. At the time of screening, eligible adults
(C 18 years) required a physician diagnosis of
chronic plaque psoriasis (C 6 months duration);
current or recent history (within 3 months) of
moderate or severe genital involvement (per
Patient Global Assessment C 4, 6-point scale
from 0 to 5); confirmation by a dermatologist of
overall psoriasis, affected body surface area
C 1%, and plaque psoriasis in extragenital areas;
and intolerance of or failure to respond to C 1
topical therapy, which included
over-the-counter topicals, for GenPs.
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Data Collection
A sample of up to 25 male and female patient
interviews was proposed. One-on-one inter-
views were conducted and patients could
choose to be interviewed in-person or on the
telephone. Interviews were conducted between
August 19, 2015 and November 19, 2015 by
trained Evidera research associates (2 females
[PhD, BS], 1 male [MS, RPh]), including JLP,
PhD (author). Patients were asked if they pre-
ferred a gender-matched interviewer or had no
preference, and a preference, when expressed,
was matched when possible. All interviewers
had at least 18 months’ experience in the con-
duct of qualitative interviews and had received
specific training for this study protocol. Prior to
telephonic interviews, packets containing the
informed consent form were mailed to subjects.
Interviewers’ reasons and interests in the
research topic were described in the informed
consent forms. Patients completed a brief
sociodemographic questionnaire during the
interview.
Each patient’s interview was completed in
one session lasting approximately 2 h. When
finished, patients were remunerated for their
time (estimated as fair market value). Upon
completion of an interview, clinic site staff
completed a clinical questionnaire on the
medical history for each patient which included
date of diagnosis with overall psoriasis and
GenPs, affected body surface area, severity of
GenPs, current GenPs status, and current GenPs
medications. During the interview, GenPs was
defined for women as symptoms of psoriasis
that occur ‘‘on the outer lip, the inner lip, and
the area between your vagina and the anus’’ and
for men as ‘‘the area of the penis, the scrotum,
and the area between the penis and the anus.’’
Data Analysis
The data for this paper focus largely on the
concept elicitation interview component; the
exception is that sex life satisfaction data
derives from the Sexual Function Questionnaire
administered during the cognitive interview
component. All patient interviews were
audio-recorded, transcribed by a third-party
professional transcriber, and reviewed by the
study team for quality assurance purposes. Per-
sonal health information was redacted and
obvious transcription errors were corrected.
A content analysis approach was used to
analyze the qualitative data (based on notes,
transcripts, and audio recordings) from the
interviews [16]. This approach uses empirical
data to validate that measurement tools and
their underlying conceptual framework are
consistent with the experiences and perspec-
tives of patients. Based on the semi-structured
interview guide and further refined by addi-
tional specific details that emerged from the
interviews, a coding dictionary was developed
by a member of the research team (JLP). One
research associate coded the transcripts and all
coding was reviewed by JLP. A qualitative
analysis software program, ATLAS.ti (version
7.5.9, Scientific Software Development GmbH,
Berlin, Germany), was used by the study team to
systematically identify and code themes within
the transcripts which were then organized in
chronological order by date of interview and
tabulated to document and quantify the emer-
gence of concepts related to the study objec-
tives. Data were organized chronologically in
order to determine the point at which satura-
tion of concepts was reached. Saturation, the
point at which gathering additional data does
not yield additional new concepts, was reached
with the 20 interviews. Descriptive statistics
(mean, standard deviation, frequency) were
used to characterize the sociodemographic and
clinical characteristics of the population.
RESULTS
Patients
Of the 25 screened patients, 22 met the inclu-
sion criteria. Two eligible subjects were
unavailable for participation, and 20 patient
interviews and clinical assessments were com-
pleted. All patients chose telephonic interviews
and declined face-to-face meetings.
The mean age was 45 years (range 21–68),
55% (n = 11) were female, and 90% (n = 18)
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were white (Table 1). The mean durations since
diagnosis for overall psoriasis and GenPs were
18 and 7.5 years, respectively, but seven
patients (35%) were diagnosed with overall
psoriasis and GenPs during the same year, and
the relative timing of their two diagnoses is
unknown. At the time of their interview, in the
3 months prior, most patients (n = 13, 65%)
reported current/recent moderate-to-severe
overall psoriasis (n = 8, 40% rated it severe), and
the majority (n = 14, 70%) reported current/re-
cent moderate-to-severe GenPs (n = 6, 30%
rated it severe). (Note that all patients met the
study criteria at screening per the requirements
of the protocol.) Current extragenital psoriasis
was most common on the scalp (n = 17, 85%),
Table 1 Patient demographics and clinical characteristics
Characteristics N Total
Age (years), mean (SD) 20 45 (14.2)
Gender (female), n (%) 20 11 (55)
Race (white), n (%) 20 18 (90)
Duration of psoriasis diagnosis
(years), mean (SD)a
19 18 (14)
Duration of genital psoriasis
diagnosis (years), mean (SD)a
20 7.5 (9.7)
Body surface area, mean (SD)a 15 10.4 (12.7)
Currently receiving treatment for
genital psoriasis,a,b,c n (%)
20 14 (70)
Biologics including investigational
products
– 11 (55)
Topicals (including OTC) – 7 (35)
Phototherapy – 0
Self-reported genital psoriasis symptom
severity at its worst over the past
3 months, n (%)
20
0–1 (0 = clear) – 0
2–3 – 6 (30)
4–5 (5 = severe) – 14 (70)d
Self-reported overall psoriasis symptom
severity at its worst over the past
3 months, n (%)
20
0–1 (0 = clear) – 1 (5)
2–3 – 6 (30)
4–5 (5 = severe) – 13 (65)
Self-reported current localization of
psoriasis other than genital psoriasis,c
n (%)
20
Scalp – 17 (85)
Hands, feet, and/or nails – 13 (65)
Face – 11 (55)
Table 1 continued
Characteristics N Total
Skin folds (i.e., armpits, under the
breasts)
– 10 (50)
Other (responses included: limbs,
buttocks, trunk, knees, elbow, ears)
– 14 (65)
Sexual activity status, n (%) 20
Active – 9 (45)
Not active – 9 (45)
Not askede – 2 (10)
OTC over the counter, SD standard deviation
a Patient clinical characteristics as reported by clinicians
b N = 13 patients self-reported that they were currently
receiving treatment for psoriasis. From the clinical forms,
current treatment was documented by clinic site staff for
N = 14 patients
c Responses not mutually exclusive
d All patients met study criteria at screening of self-re-
ported genital psoriasis (Patient Global Assessment C 4,
6-point scale); these data report status at the time of the
interview
e Per interviewers’ judgment, the question was not asked
due to auditory cues, conversation ﬂow, and patient’s
apparent lack of comfort with sensitive topics
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and hands, feet, and/or nails (n = 13, 65%)
(Table 1). Seventy percent of patients were cur-
rently receiving at least one GenPs treatment
which included biologics (n = 11, 55%) and
topicals (n = 7, 35%).
Patient-Reported Genital Psoriasis
Symptoms
Patients reported multiple genital symptoms.
The most commonly reported were itch and
discomfort (both n = 20, 100%), redness
(n = 19, 95%), stinging/burning (n = 19, 95%),
pain (n = 17, 85%), and scaling (n = 17, 75%)
(Fig. 1a). Thirty percent (n = 6) of patients
reported cracking. Patients also reported flaking
(n = 4, 20%), dry skin (n = 3, 15%), pimples
(n = 2, 10%), being more susceptible to illness
(n = 2, 10%), bleeding, inflammation, irritation,
mental discomfort, oozing, bad odor, and
swelling (each n = 1, 5%). Of these, the ‘‘most
bothersome’’ symptoms (patients could report
C 1 symptom) were itch and stinging/burning
(both n = 8, 40%).
Qualitatively, gender differences were
observed. All females (n = 11, 100%) reported
experiencing itch and discomfort, whereas all
males (n = 9, 100%) reported itch, discomfort,
redness, stinging/burning, and pain (Fig. 1a).
Half of females reported itch as the most both-
ersome symptom (n = 6, 55%) (Fig. 1b) whereas
males reported stinging/burning as the most
bothersome symptom (n = 4, 44%) (Fig. 1c).
Differences Between Genital
and Nongenital Psoriasis Symptoms
Most patients (n = 18, 90%) reported that some
aspect of GenPs was more intense and/or
unique compared to extragenital psoriasis (see
Table 2 for representative patient quotations).
Several features were identified. First was the
constant intensity of, awareness of, and/or need
to manage a symptom in GenPs versus in other
locations. Itching was commonly reported for
its intensity, and in some cases patients scrat-
ched until bleeding occurred. Second was the
sensation of pain, particularly that linked to
itching. The pain sensation could have the
effect of limiting sexual activity and social life
(below). Finally, two patients reported feeling
self-conscious that their GenPs might be
misidentified as a sexually transmitted disease.
Patients attributed the differences with GenPs
as due to thinner, more tender skin, more
moistness and sweat, greater impact from sweat,
increased friction from skin or clothes, and
topical treatments not lasting as long.
Fig. 1 Frequency of patient reported genital psoriasis
symptoms. Patients with current or recent (B 3 months)
moderate-to-severe GenPs were asked an open-ended
question (without any deﬁnition of symptoms) about the
GenPs symptoms they experienced and were also ques-
tioned on predeﬁned symptoms, whether spontaneously
reported or not. Patients were asked which symp-
tom(s) were the most bothersome (patients could report
more than one symptom). a Frequency of symptoms.
b Most bothersome symptom(s) for females (N = 11).
c Most bothersome symptom(s) for males (N = 9)
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Effect of Genital Psoriasis on Sexual
Activity
A higher percentage of men reported being
‘‘currently sexually active’’ than women (67%
versus 27%). GenPs affected many aspects of
sexual health. Nearly all patients (n = 18, 90%)
reported at least one negative impact on sexual
activity. These included impaired sexual expe-
rience during sexual activity (n = 16, 80%) (de-
fined broadly to include intercourse and
activities such as masturbation), worsening of
symptoms after sexual activity (n = 16, 80%),
decreased sexual frequency (n = 16, 80%),
Table 2 Patient-reported differences between genital and nongenital psoriasis
Representative patient quotations
Itch
[On my arms and legs] it’s just itching, and I scratch it until the itch goes away. But the only place I’ve ever bled was in
my genitals because I scratch so much. (F)
It’s totally different. It’s like the itch you can’t ever get rid of it. (F)
[My other psoriasis] itches, it may be 5 or 7 intermittently, but there’s almost never pain, burning. [Genital psoriasis]
itches 24 h a day, a subliminal pain or itch. You can’t scratch it 24 h a day. Then because you’re not scratching it, the
itch becomes a discomfort, a distraction. (M)
Pain
Other places on my body might itch more, but genital psoriasis is deﬁnitely one that hurts the most. (M)
The psoriasis I have on my elbows and my knees, there…may be a little discomfort associated. But it’s certainly nothing
that affects how I live my life. Whereas the psoriasis has resulted in behavioral changes on the genital side. The pain
would be really only in the genital area. (F)
This is a different pain. With my psoriasis on the other parts of my body, it’s like some mornings I can’t even get out of
bed it hurts so bad. (F)
Discomfort
When you walk, sit, stand, you are always using that area. I can’t not notice the discomfort. (F)
I don’t really have pain with it. But you can’t dry [that area] out so it stays wet and sore all the time. (F)
Stinging/burning
The itching is worse on my scalp where I have the thick erythema. The burning is worse in the genital area, it’s like
putting a hot match head on your skin. (M)
Cracking
The other parts of my body all hurt. But they doesn’t ever crack and bleed like my penis and scrotum area…When it
cracks it’s exposed to this newer skin so it’s very, very sensitive. Showers are always painful for the ﬁrst or second day.
(M)
Mistaken for STD
I become more self-conscious…a sexual partner or someone else may possibly perceive that as a sexually transmitted
disease. (M)
F female, M male, STD sexually transmitted disease
Semi-structured interviews were conducted with 20 patients with genital psoriasis. Selected quotations are from patients and
have been edited to minimize repetitive language
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avoidance of sexual relationships (n = 15, 75%,
which men reported more frequently than
women, 89% vs 64%), and reduced sexual desire
(n = 11, 55%) (Fig. 2a). In the week prior to the
interview, half of patients reported that GenPs
affected their sex life satisfaction ‘‘quite a bit’’ or
‘‘very much’’ (each n = 5, 25%), 30% (n = 6)
responded ‘‘not at all,’’ 10% (n = 2) reported
‘‘somewhat,’’ 5% (n = 1) reported ‘‘a little bit’’,’’
and 1 patient (5%) had not had GenPs symp-
toms in the past week. Nearly half (45%) of
patients reported sexual inactivity (Table 1), but
they were not asked if the current inactivity was
related to GenPs or another reason.
Negative effects on sexual experience
encompassed physical effects such as mechani-
cal friction, cracking, and pain and psychosocial
effects such as embarrassment and feeling stig-
matized. The physical effects could linger for
hours, if not days, as prolonged pain and dis-
comfort. This led some patients to intervene
with immediate self-made treatments (such as
bathing in Epsom salts) to control post-activity
symptoms. Some patients described proactively
weighing the value of a potential intimate
encounter against its potential subsequent pain
and discomfort. Not surprisingly, decreases in
frequency and avoidance of sexual relationship
were common. Patients not in relationships
described embarrassment or a reluctance to
reveal their GenPs to someone, and those in
long-term relationships, even with understand-
ing partners, described the emotional toll their
avoidance incurred on the relationship (quota-
tions in Table 3).
Effect of Genital Psoriasis on Nonsexual
Aspects of HRQoL
GenPs led to impairment of HRQoL beyond
sexual health, including on mood/emotion
(n = 19, 95%), physical activities (n = 14, 70%),
daily activities (n = 12, 60%), social or leisure
activities (n = 9, 45%), relationships with
friends and family (n = 9, 45%), and work or
school (n = 7, 35%) (Fig. 2b). Patients reported
feeling stressed, frustrated, angry, anxious,
depressed, sad, and embarrassed due to GenPs,
which could trigger distraction, self-conscious-
ness, lowered self-esteem or confidence, feeling
less desirable, helplessness hopelessness, con-
cern for the future, and wondering ‘‘why me?’’
The physical component was affected by
symptoms and flares which inhibited physical
activities (such as walking, running, or swim-
ming in chlorinated pools), and by increased
friction and sweat (e.g., a longer work day,
increased sweating from exertion or weather
conditions, or not being able to treat symptoms
promptly). Even sitting was reported to be
Fig. 2 Frequency of patient-reported impacts from genital
psoriasis. Patients with current or recent (B 3 months)
moderate-to-severe GenPs were asked an open-ended
question about the impact GenPs had on their lives and
were also questioned on prespeciﬁed impacts, whether
spontaneously reported or not. a Frequency of sexual
impacts. b Frequency of nonsexual impacts. aPer inter-
viewers’ judgment, the question was not asked of one
patient due to auditory cues, conversation ﬂow, and the
patient’s apparent lack of comfort with sensitive topics.
bPer interviewers’ judgment, the question was not asked of
two patients due to auditory cues, conversation ﬂow, and
the patients’ apparent lack of comfort with sensitive topics
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uncomfortable by some patients. Other factors
which worsened GenPs included stress, dryness
in winter, lack of sleep, and drinking alcohol.
The impairments led patients to eliminate cer-
tain physical activities, reduce intensity, or
limit the number of activities in a day (quota-
tions in Table 4).
These impacts significantly affected daily
activities, such as painful urination and poor
sleep hygiene due to difficultly in falling asleep
Table 3 Patient-reported impacts of genital psoriasis on sexual activity
Representative patient quotations
Negative effects on sexual experience
Foreplay, that is almost unheard of because of the friction and the irritation. (F)
The stinging during sex, it is just a terrible feeling. (M)
When psoriasis cracks, it’s like a paper cut. And if I get a full erection, I’d get three or four of those, laterally, along the
side of the penis. The pain was unbelievable. (M)
Deﬁnitely the embarrassment… I’ve had one boyfriend make a comment, is that, what’s this? (F)
Even during the course of a long-term relationship, I still can’t get it out of my mind how I feel slightly more judged by
it, even if I’m not being so. (M)
Worsening of symptoms after activity
It just makes the itch worse. (F)
During [intercourse] hurts because of getting an erection and elongating the penis…then afterwards is when you notice
the majority of the pain…from the friction and the rubbing and this newer exposed red skin that is very sore and
tender. (M)
[Deciding to have sex] is a calculated decision as to what the cost is going to be and pain and discomfort post-activity for
hours and/or days. (M)
If his stuff gets on there, it sets it on ﬁre…you just have to immediately sit in another Epsom salt bath…it’s just like
three days…of hell, so it’s not worth it to me. (F)
Decreased sexual frequency
Post-[genital] psoriasis, I’m not nearly as active as I was. (M)
Avoidance of sexual relationship
I told him…if it comes between having sex—because it’s so painful—and…not being married, then I choose not to be
married. (F)
There’s no sex life. First of all, you don’t want to expose yourself. But I’m single and I don’t want to think about dating
because I’m not ready to share with a stranger. (F)
I pursue my own pleasure a lot less…I’m really not interested in pleasure if it’s associated with pain. So, I rarely initiate
intimacy which is devastating [and] hurts my husband’s feelings. (F)
To be honest with you, I kind of stay withdrawn from too much contact with the wife, I don’t want it to lead to
anything. (M)
Semi-structured interviews were conducted with 20 patients with genital psoriasis. Selected quotations are from patients and
have been edited to minimize repetitive language
F female, M male
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Table 4 Patient-reported impact of genital psoriasis on nonsexual HRQoL
Representative patient quotations
Mood/emotion
The pain brings on discomfort and then it just triggers everything else, the stress and the anxiety and emotions and
everything… It all just works together against me. (F)
The redness is not really terribly uncomfortable anymore if I take care of it, but it’s always there. And that’s kind of a
mental thing. (M)
It’s affected my life in so many ways. What I can wear, what activities I can involve myself in…I don’t really like to do a
whole lot because I am feeling discomfort with the stress, and lack of conﬁdence whether it be with my partner
or…just everyday life. (F)
Physical activity
If it’s ﬂaring up and the skin is very raw, I can’t [go for a run] because of the friction. I don’t swim anymore, not in
chlorine. (M)
It gets worse if I’m working in the yard or playing with my dogs or… moving around more, it naturally becomes more
irritated… Walking, sitting, you can’t sit comfortably. Walking, that’s the worst painfulness. (F)
I try to keep cream and powder down there so I won’t itch when I’m working around people… [But] if I’ve been
outside working out in the heat or if I’ve been doing a lot of sweating, it’s really bad. (F)
It does not bother me much but if I work a 10- or 12-hour shift, it begins to itch and then I cannot wait to get home to
shower and clean things and put more medication on. (M)
Daily activities
You’re laying [sic] in bed at night and you can’t get comfortable because no matter how you turn, that signal, that
sensory signal goes there. (M)
Especially when I go to the bathroom. Urine burns. It really burns it. (F)
I am uncircumcised…and it’s difﬁcult and even painful to pull the foreskin back to urinate or for sexual activities as
well. (M)
[When it cracks] I wrap [my penis] in toilet paper to keep it from burning or stinging or touching my boxers or
anything. (M)
Sometimes when you sit in a chair, it’s not comfortable or you always feel like you want to pull your panties away from
your body. (F)
The skin is very, very thin and any friction or irritation, even underwear, is uncomfortable. (M)
You always have to be prepared and carry around panty liners…when it’s bad, if I have on a pair of shorts and I sit
down on a cushion, you know, things might leak through [due to oozing]. That’s what I call high maintenance. (F)
Dr. X has given me creams and stuff…but they wash off when I go to the bathroom. I always wear a pad just in case it
starts to bleed. (F)
And if you’re sweating or you’re active or your shorts bunch up, it becomes very uncomfortable. But it’s chronic…you
may not notice it for an hour, but you don’t go 6 hours without it being noticeable. (M)
10 out of 10 is when…everything is so bad that I actually get nauseous from it, have to run to the bathroom and wash
the area. (F)
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and unconscious scratching while sleeping.
Patients reported many common practices in
their daily life to control symptoms. These
included, for example, choosing loose-fitting
clothes based on comfort, daily routines of a
shower or soaking bath, needing to carry certain
supplies (e.g., ointments and creams to treat
symptoms, panty liners because of oozing), or
taking specific precautions (e.g., a male patient
wrapped his penis in tissue paper during periods
of post-cracking hypersensitivity). These
HRQoL impairments led to decreased interac-
tions with family and friends and social net-
works as some patients reported that their
symptoms lead them to be nonsocial (e.g., fear
of itching badly and not being able to scratch in
social situations, fear of nakedness in front of
others, etc.) (quotations in Table 4).
Patients also described learning to cope with
their GenPs, which included finding treatment
regimens and routines that reduced symptoms
and improved their quality of life.
General Themes
General themes emerged. A first theme was
the constant intensity and/or awareness of
some aspects of GenPs, such as itching, fric-
tion, or symptoms that repeated themselves in
a continuous cycle. A second theme was that
GenPs presented some different challenges
than extragenital psoriasis (i.e., intensified
sensation of pain or discomfort and being
associated with the stigma of sexually trans-
mitted diseases). A third was the toll of GenPs
on sexual life and relationships, whether in
actual or potential situations. The final theme
was the mental and emotional strain of
GenPs. Patients spoke of being distracted
during social interactions, isolating them-
selves, needing to be always vigilant in their
efforts to control symptoms, and learning to
ignore their symptoms and ‘‘turn it off’’ and
‘‘not let it get me down.’’
DISCUSSION
This qualitative study of patients with moder-
ate-to-severe GenPs showed that GenPs led to
multiple specific psychosexual and psychosocial
impairments. Symptoms were reported to be
more intense and/or constant in GenPs than in
extragenital psoriasis, and nearly all patients
reported negative impacts on both sexual and
nonsexual quality of life. The disproportionate
impact of GenPs has been recognized by some
treatment and consensus guidelines. Due to the
physical, emotional, and social burden of GenPs
on patients, guidelines for the treatment of
psoriasis suggest that even in patients with low
body surface area involvement, involvement of
genital skin may justify its classification as
moderate or severe disease and thus warrant
systemic treatment, especially if topical treat-
ments are ineffective [17, 18].
Table 4 continued
Representative patient quotations
Personal relationships
I was embarrassed and thought there was something wrong with me…I had all these concerns…that no one will ever
want me. I won’t be able to have a girlfriend or wife. (M)
I’m not social any more. I’ve become a recluse…if it starts itching or something…it’s not seemly that you would be able
to take care of yourself in a public situation. (F)
It’s not like I ever want to be naked around anyone when that’s going on. So from showering in a locker room to in a
relationship, it puts you on a more guarded and different level. (M)
Semi-structured interviews were conducted with 20 patients with genital psoriasis. Selected quotations are from patients and
have been edited to minimize repetitive language
F female, M male
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The level of reported symptoms in this study
was high. The majority of our patients reported
current/recent moderate-to-severe GenPs, and
the high level of reported GenPs symptoms
likely reflects this disease burden. In terms of
reported symptoms, all patients reported itch,
which is common to GenPs patients [12] as well
as to patients with extragenital psoriasis
(77%–88%) [19–21]. Itch was also reported as
one of the most bothersome symptoms, con-
sistent with the study by Meeuwis and col-
leagues [4] in which GenPs patients reported
itch and redness had the ‘‘highest intensity.’’
The impact of GenPs described by patients in
this study was pronounced. Patients with pla-
que psoriasis in extragenital locations already
report impairment of sexual health [22–25], but
the presence of GenPs incurs an additional toll
[3, 5]. This current study sheds light on the
impact of high GenPs disease burden on mul-
tiple aspects of sexual experience and relation-
ships. The reported high level of nonsexual
impacts, particularly on mood/emotions, phys-
ical activities, and daily activities, is supported
by the findings of more severe impairment on
HRQoL [3, 5] and greater depression [5, 13] in
psoriasis patients with versus without genital
involvement. Psoriasis patients with pain expe-
rience interference with function significantly
more frequently and more severely compared to
patients with skin discomfort [26]. The high
rates of reported pain and discomfort in this
study underscore their impact on emotions and
daily life.
Interesting differences were observed
between men and women in this study. Men
not only reported a higher symptom frequency
burden than women, but 8 of the 9 men also
reported significant sexual impacts. The most
bothersome symptoms differed, with itch being
most bothersome for women and stinging/
burning most bothersome for men. These find-
ings may reflect the higher prevalence in this
study of cracking in men or biological and/or
psychological differences between the genders
[4]. Despite their higher burden, men reported a
higher level of sexual activity and greater
avoidance of sexual relationships than women,
which could suggest that more men maintained
sexual activity through masturbation.
One important finding was the time lag
between mean diagnosis of general psoriasis
and GenPs, with the diagnosis of extragenital
psoriasis predating that of GenPs for many
patients. Given that estimates of the proportion
of psoriatic patients with a current or past his-
tory of GenPs range from 32% to 63% [1–5],
patients with psoriasis are at risk for developing
GenPs. The disease currently engenders reluc-
tance amongst patients and even some health
care providers to discuss it or physically exam-
ine the genital area, yet it can significantly
impact many facets of patient quality of life.
Providers should consider genital involvement
as a possibility in patients with psoriasis and
provide appropriate follow-up.
The extent to which these findings can be
generalized to all GenPs patients may be lim-
ited. The overall sample size (N = 20) and gen-
der subgroups (11 females and 9 males) were
small and geographically limited to four states
in the continental US. Racial minorities were
underrepresented. Sexual identity was not eli-
cited during the interview and the perspectives
of patients in same-sex relationships or trans-
gender patients were not explicitly represented.
Recruitment occurred in clinics and patients
not seeking allopathic care were underrepre-
sented. Patients with greater impairments may
be more inclined to share their experience,
leading to selection bias, and other biases dur-
ing the interviews or data interpretation could
have come into play. The finding that all
patients preferred telephone, rather than face--
to-face, interviews leads the authors to specu-
late that the social distance afforded by the
telephone may reflect patients’ embarrassment
or discomfort.
CONCLUSIONS
In conclusion, this qualitative study of patients
with high rates of moderate-to-severe GenPs
reportedmultiple psychosexual and psychosocial
impairments from their GenPs symptoms. The
details of patients’ ‘‘lived experience’’ in illumi-
nating theburdenand impactofGenPs attests toa
role for qualitative research in psoriasis research
[19, 27]. Given the chronic nature of psoriasis,
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providersmaywant to consider that patientswith
psoriasis may have or could develop genital
involvement. Future studies should look at treat-
ments which help patients with GenPs maintain
or achieve a higher level of quality of life and
sexual functioning. Additionally, studies are nee-
ded to examine the factors involved in the reluc-
tance of health care providers and patients to
discuss GenPs and its impact on HRQoL. Lastly,
patients’ subjective quality of life is an important
factor in determining appropriate treatment and
should be considered in addition to the total body
surface area of involvement.
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